Teva not a one-man show

Regarding his perceived quick departure, Makov said he was leaving while the company was at the top, refuting speculation that he had been ousted over disagreements with Chairman Eli Hurvitz.

By SHARON WROBEL
November 8, 2006 07:06

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Israel Makov, the President and CEO of Teva, who announced his resignation three weeks ago, is confident his successor Shlomo Yanai, CEO of Makteshim Agan, despite being new to the pharmaceutical industry, will establish himself with the help of the company's management. "Teva is not a one-man show. We have the best management team in the industry," Makov told The Jerusalem Post. "We will help and teach Yanai as long as need be." Regarding his perceived quick departure, Makov said he was leaving while the company was at the top, refuting speculation that he had been ousted over disagreements with Chairman Eli Hurvitz.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS